Investors & Media

Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

SEC
SEC Filings
Form Description Document Date
4

Statement of changes in beneficial ownership of securities

144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

8-K

Report of unscheduled material events or corporate event